GS-9450 + GS-9450 Placebo

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nonalcoholic Steatohepatitis

Conditions

Nonalcoholic Steatohepatitis

Trial Timeline

Aug 1, 2008 → Sep 1, 2009

About GS-9450 + GS-9450 Placebo

GS-9450 + GS-9450 Placebo is a phase 2 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00740610. Target conditions include Nonalcoholic Steatohepatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00740610Phase 2Completed
NCT00725803Phase 2Completed

Competing Products

20 competing products in Nonalcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Colesevelam HclDaiichi SankyoPhase 2
52
Tirzepatide + PlaceboEli LillyPhase 2
52
AZD2693AstraZenecaPhase 2
52
Roflumilast + Pioglitazone + Placebo + PlaceboAstraZenecaPhase 2
52
MK-3655 + PlaceboMerckPhase 2
52
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mLMerckPhase 2
52
SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3
76
Seladelpar + PlacebosGilead SciencesPhase 2
51
CilofexorGilead SciencesPhase 1
32
Firsocostat + FenofibrateGilead SciencesPhase 1
32
GS-9674 + Placebo to match GS-9674Gilead SciencesPhase 2
51
SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SELGilead SciencesPhase 2
51
Semaglutide + Firsocostat + CilofexorGilead SciencesPhase 2
51